循環器ジャーナル69巻4号

2021年10月発行

特集 プレシジョン・メディシン時代における腫瘍循環器学の重要性 序章

新しい学際領域としての腫瘍循環器学—循環器医の立場から

著者： 小室一成¹

所属機関： ¹東京大学大学院医学系研究科循環器内科学

ページ範囲：P.506 - P.513

Point
・治療の進歩によるがん患者の予後の向上によって，循環器病を併発することが増えている．
・がん治療に伴って多くの循環器病が併発するが，特に心不全が重要である．
・がん患者には血栓塞栓症が併発しやすいが，同時に出血も多い．
・世界的に腫瘍循環器学が注目されているが，わが国においても日本腫瘍循環器学会が設立された．

参考文献

1) Patnaik JL, Byers T, DiGuiseppi C, et al:A Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer:a retrospective cohort study. Breast Cancer Res 13:R64, 2011

2) Lenneman CG, Sawyer DB:Cardio-Oncology:An Update on Cardiotoxicity of Cancer-Related Treatment. Circ Res 118:1008-1020, 2016

3) Zamorano JL, Lancellotti P, Muñoz DR, et al:2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology（ESC）. Eur Heart J 37:2768-2801, 2016

4) Felker GM, Thompson RE, Hare JM, et al:Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342:1077-1084, 2000

5) Ewer MS, Vooletich MT, Durand JB, et al:Reversibility of trastuzumab-related cardiotoxicity:new insights based on clinical course and response to medical treatment. J Clin Oncol 23:2900-2902, 2005

6) Ewer MS, Ewer SM:Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 12:547-558, 2015

7) Zhang S, Liu X, Bawa-Khalfe T, et al:Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18:1639-1642, 2012

8) Higo T, Naito AT, Sumida T, et al:DNA single-strand break-induced DNA damage response causes heart failure. Nat Commun 8:15104, 2017

9) Aminkeng F, Bhavsar AP, Visscher H, et al:A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat Genet 47:1079-1084, 2015

10) Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, et al:Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. Circulation 140:31-41, 2019

11) Ichikawa Y, Ghanefar M, Bayeva M, et al:Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest 124:617-630, 2014

12) Jones RL, Wagner AJ, Kawai A, et al:Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. Clin Cancer Res 27:3861-3866, 2021

13) Folkman J:Tumor angiogenesis:therapeutic implications. N Engl J Med 285:1182-1186, 1971

14) Johnson DB, Balko JM, Compton ML, et al:Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med 375:1749-1755, 2016

15) Wang DY, Salem JE, Cohen JV, et al:Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors:A Systematic Review and Meta-analysis. JAMA Oncol 4:1721-1728, 2018

16) Varki A:Trousseau's syndrome:multiple definitions and multiple mechanisms. Blood 110:1723-1729, 2007

17) Khorana AA:Venous thromboembolism and prognosis in cancer. Thromb Res 124:490-493, 2010

18) Walker AJ, Card TR, West J, et al:Incidence of venous thromboembolism in patients with cancer-a cohort study using linked United Kingdom databases. Eur J Cancer 49:1404-1413, 2013

19) Blom JW, Doggen CJM, Osanto S, et al:Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715-722, 2005

20) Raskob GE, van Es N, Verhamme P, et al:Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med 378:615-624, 2018